testing all

Pharmaceutical Biotechnology (Record no. 2277)

MARC details
000 -LEADER
fixed length control field 01354 a2200301 4500
001 - CONTROL NUMBER
control field 1420044370
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250317100410.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 250312042007xx 227 eng
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9781420044379
037 ## - SOURCE OF ACQUISITION
Source of stock number/acquisition Taylor & Francis
Terms of availability GBP 82.99
Form of issue BB
040 ## - CATALOGING SOURCE
Original cataloging agency 01
041 ## - LANGUAGE CODE
Language code of text/sound track or separate title eng
072 7# - SUBJECT CATEGORY CODE
Subject category code PS
Source thema
072 7# - SUBJECT CATEGORY CODE
Subject category code TDCW
Source thema
072 7# - SUBJECT CATEGORY CODE
Subject category code PS
Source bic
072 7# - SUBJECT CATEGORY CODE
Subject category code TDCW
Source bic
072 7# - SUBJECT CATEGORY CODE
Subject category code MED071000
Source bisac
072 7# - SUBJECT CATEGORY CODE
Subject category code SCI013000
Source bisac
072 7# - SUBJECT CATEGORY CODE
Subject category code 615.19
Source bisac
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Daan J. A. Crommelin
245 10 - TITLE STATEMENT
Title Pharmaceutical Biotechnology
Remainder of title Fundamentals and Applications, Third Edition
250 ## - EDITION STATEMENT
Edition statement 3
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. CRC Press
Date of publication, distribution, etc. 20071030
300 ## - PHYSICAL DESCRIPTION
Extent 512 p
520 ## - SUMMARY, ETC.
Expansion of summary note Completely revised text that reflects to emergent trends and cutting-edge advances in pharmaceutical biotechnology, this Third Edition provides a well-balanced framework for understanding every major aspect of pharmaceutical biotechnology, including drug development, production, dosage forms, administration, and therapeutic developments. New chapters cover evolving areas regarding biopharmaceuticals, including oligonucleotides, siRNA and various monoclonal antibodies, immunogenicity, gene therapy, and the regulatory issues factoring into the biopharmaceutical approval process
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Robert D. Sindelar
Relationship B01
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Bernd Meibohm
Relationship B01

No items available.